ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Chinook Therapeutics, Inc. (KDNY) stock surged +0.22%, trading at $40.39 on NASDAQ, up from the previous close of $40.30. The stock opened at $40.31, fluctuating between $40.30 and $40.51 in the recent session.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Employees | 214 |
Beta | 0.67 |
Sales or Revenue | $6.13M |
5Y Sales Change% | 402% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |